New Diabetes Medications for Kidney Disease
Impact of Antiglycemic & Immunosuppressive Therapies on NETosis in Diabetes & Kidney Disease (NETs - Neutrophil Traps)
Recruiting
Observational Study
Diabetes Mellitus
Kidney Disease
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 70 (estimated)
- Sponsor
- Western Galilee Hospital-Nahariya · Government
Who this trial is looking for
This trial is looking for adults with diabetes and kidney disease. Participants will be evaluated for any effects of new diabetes medications on their condition.
Are You a Good Fit for This Trial?
You may be able to join if
- I am at least 18 years old.
- I have been diagnosed with diabetes.
- I have not previously taken SGLT2 inhibitors or GLP-1 receptor agonists.
- I have chronic kidney disease.
You may not be able to join if
- I have an acute infection.
- I have a blood or cancer disease.
- I test positive for HIV.
- I test positive for Hepatitis B or C.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study aims to investigate whether new glucose-lowering medications, such as SGLT2 inhibitors (e.g., Forxiga/Jardiance) and GLP-1 receptor agonists (e.g., Ozempic), can reduce NETosis in diabetic patients, thereby mitigating secondary complications such as cardiovascular disease and kidney damage. By targeting dysregulated NET formation, the study seeks to establish a link between reduced NETo…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
DM therapy study: - Diabetic patients aged 18 years or older (men and women).
* Patients who have not previously received SGLT2 inhibitors or GLP-1 receptor agonists.
-Chronic kidney disease (CKD) patients :50 CKD patients with various etiologies.
• Focus:
* This part of …
Contacts